ArticleMedical oncology (Northwood, London, England)2013
Clinical implications of CIP2A protein expression in breast cancer.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.Disease markers · 2019Pooled it
- Pooled it
- From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer.Frontiers in genetics · 2023Review
- Fusicoccin-A Targets Cancerous Inhibitor of Protein Phosphatase 2A by Stabilizing a C-Terminal Interaction with 14-3-3.ACS chemical biology · 2022Article
- Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.OncoTargets and therapy · 2020Review
- Observational
- CIP2A overexpression in Taiwanese oral cancer patients.Cancer management and research · 2019Article
- Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.Journal of Cancer · 2019Article
- Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.Oncotarget · 2018Article
- Article
- PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2017Review
- Article
- High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.OncoTargets and therapy · 2017Article
- Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.International journal of oncology · 2016Article
- All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.The FEBS journal · 2016Review
- Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.Leukemia · 2015Article
- Article
- Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?American journal of cancer research · 2015Review
- miR-320a is an independent prognostic biomarker for invasive breast cancer.Oncology letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work is to study the expression and regulatory effects of CIP2A protein in breast cancer and the correlation between CIP2A protein expression and the prognosis of breast cancer. The CIP2A protein level was detected by immunohistochemistry staining. The relationship between CIP2A protein and clinicopathological parameters of breast cancer was determined. It was observed that 448 (35.00 %) of the 1,280 cases positively expressed CIP2A protein. Univariate analysis indicated that CIP2A expression was related to histological grade, lymph node metastasis, distant metastasis, and triple-negative breast cancer (P = 0.001, 0.001, 0.001, and 0.001, respectively). Spearman correlation analysis showed that CIP2A expression has line correlation with histological grade, lymph node metastasis, distant metastasis, triple-negative breast cancer, and TNM stage (P = 0.03, 0.001, 0.008, 0.001, and 0.001, respectively). After multivariate analysis, tumor size, histological grade, lymph node metastasis, triple-negative breast cancer, distant metastasis, and TNM stage were related to CIP2A expression (P = 0.035, 0.001, 0.028, 0.001, 0.001, and 0.001, respectively). CIP2A expression also significantly related to chemotherapeutic sensitivity of breast cancer in the neoadjuvant chemotherapy. In the Cox regression test, histological grade, lymph node metastasis, triple-negative breast cancer, and TNM stage were detected as the independent prognostic factors (P = 0.001, 0.006, 0.01, 0.011, and 0.001, respectively). CIP2A expression may be a potential biomarker for chemotherapeutic sensitivity and prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.